What changed on April 30, 2026: The FDA announced a proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B compounding bulks list
Several methodological limitations emerged
In a 56-day phase-2 trial, 9 participants with severe dry eye syndrome were treated with synthetic TB4 eye drops or placebo for 28 days, followed by a 28-day observational period
Phase I pilot (three healthy male volunteers, subcutaneous administration, 1996, PMID 8637402), increased facial, upper-body, and buttock pigmentation persisting approximately one week after cessation of dosing was reported alongside nausea and somnolence
In a double-blind crossover trial, patients with confirmed fructose malabsorption who took XI with a fructose load had lower hydrogen breath levels and fewer GI symptoms than on placebo, suggesting it may help those who experience discomfort from consuming apples, pears, honey, or high-fructose sweeteners.4 People taking GLP-1 medications (Ozempic, Wegovy, Mounjaro, etc.) GLP-1 receptor agonists commonly slow stomach emptying and cause nausea, fullness, and constipation
Unlike purely dietary approaches that often lead to yo-yo weight patterns, GLP-1 therapy provides sustained results
